Author | Leal, Juliana Vassalo Rodrigues | |
Author | Spector, Nelson | |
Author | Meis, Ernesto de | |
Author | Rabello, Lígia Sarmet Cunha Farah | |
Author | Rosolem, Maíra de Moraes | |
Author | Brasil, Pedro Emmanuel Alvarenga Americano do | |
Author | Salluh, Jorge Ibrain Figueira | |
Author | Soares, Márcio | |
Access date | 2015-06-15T15:31:37Z | |
Available date | 2015-06-15T15:31:37Z | |
Document date | 2014 | |
Citation | LEAL, Jauliana Vassalo Rodrigues et al. Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study. Journal of Critical Care, v. 29, n. 4, p.533-538, 2014. | pt_BR |
ISSN | 0883-9441 | |
URI | https://www.arca.fiocruz.br/handle/icict/10846 | |
Language | eng | pt_BR |
Publisher | Elsevier | pt_BR |
Rights | restricted access | pt_BR |
Title | Antiphospholipid antibodies in critically ill patients with cancer: a prospective cohort study | pt_BR |
Type | Article | pt_BR |
DOI | 10.1016/j.jcrc.2014.02.005 | |
Abstract | Purpose: The purpose of this study is to evaluate the prevalence and the prognostic impact of antiphospholipid
antibodies (aPL) in critically ill cancer patients.
Methods: This is a prospective cohort study in adult patients admitted to the intensive care unit for more than
48 hours at a cancer center. Clinical and laboratory data including coagulation parameters were obtained. Cox
proportional hazard models were used to identify predictors of 6-month mortality.
Results: Ninety-five (solid tumor, 79%; hematologic malignancies, 21%) patients were included, and aPL were
identified in 74% of them. Median Simplified Acute Physiology Score 3 and Sequential Organ Failure
Assessment scores were 51 (37-65) and 5 (2-8) points, respectively. The most frequent aPL were lupus
anticoagulant (61%) and anti-β2 glicoprotein I (32%). Vascular complications occurred in 18% of patients and
were comparable between aPL+ and aPL− patients. Sepsis and need for renal replacement therapy were
more frequent in aPL+patients. Hospital and 6-month mortality rates were 44% and 56%, respectively. Higher
Sequential Organ Failure Assessment scores (each point) (hazard ratios [HR]=2.83 [95% confidence interval,
1.59-5.00]), medical admissions (HR=2.66 [1.34-5.27]), and D-dimer more than 500 ng/dL (HR=1.89 (1.04-
3.44]) were independently associated with mortality. After adjusting for these covariates, aPL status was not
associated with outcomes (HR = 1.22 [0.60-2.47]).
Conclusions: Lupus anticoagulants were frequent in critically ill cancer patients. However, they were not
associated with medium-term survival in these patients. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Programa de Pós-Graduação. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Programa de Pós-Graduação. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Instituto Nacional de Câncer. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Programa de Pós-Graduação. Rio de Janeiro, RJ, Brasil / Instituto Nacional de Câncer. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Instituto Nacional de Câncer. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Doença de Chagas. Rio de Janeiro, RJ, Brasil / Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Programa de Pós-Graduação. Rio de Janeiro, RJ, Brasil / Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Instituto Nacional de Câncer. Programa de Pós-Graduação. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Universidade Federal do Rio de Janeiro. Programa de Pós-Graduação. Rio de Janeiro, RJ, Brasil / Instituto D'Or de Pesquisa e Ensino. Rio de Janeiro, RJ, Brasil / Instituto Nacional de Câncer. Programa de Pós-Graduação. Rio de Janeiro, RJ, Brasil. | pt_BR |
Subject | Antiphospholipid antibodies | pt_BR |
Subject | Prognosis | pt_BR |
Subject | Intensive Care Units | pt_BR |
Subject | Neoplasms | pt_BR |
DeCS | Anticorpos antifosfolipídeos | pt_BR |
DeCS | Prognóstico | pt_BR |
DeCS | Unidades de Terapia Intensiva | pt_BR |
DeCS | Neoplasias | pt_BR |
e-ISSN | 1557-8615 | |